In a novel syngeneic preclinical model of ER + mammary carcinoma [59] efficacy of radiotherapy combined with CDK4/6 inhibitor palbociclib and tamoxifen were investigated in various doses and therapeutic schedules [60]. This evidence concerns the gene CDK4 and breast carcinoma.